Cancer Research and Treatment

Original Articles

General

Immunogenicity and Safety of Vaccines against Coronavirus Disease in Actively Treated Patients with Solid Tumors: A Prospective Cohort Study: Yae Jee Baek, Youn-Jung Lee, So Ra Park, Kyoo Hyun Kim, Seung-Hoon Beom, Choong-kun Lee, Sang Joon Shin, Sun Young Rha, Sinyoung Kim, Kyoung Hwa Lee, Jung Ho Kim, Su Jin Jeong, Nam Su Ku, Jun Yong Choi, Joon-Sup Yeom, Minkyu Jung, Jin Young Ahn; Cancer Res Treat. 2023;55(3):746-757. Published online February 9, 2023; DOI: https://doi.org/10.4143/crt.2022.1541

Abstract PDF Supplementary Material PubReader ePub

Purpose
We aimed to assess the humoral response to and reactogenicity of coronavirus disease 2019 (COVID-19) vaccination according to the vaccine type and to analyze factors associated with immunogenicity in actively treated solid cancer patients (CPs).
Materials and Methods
Prospective cohorts of CPs, undergoing anticancer treatment, and healthcare workers (HCWs) were established. The participants had no history of previous COVID-19 and received either mRNA-based or adenovirus vector–based (AdV) vaccines as the primary series. Blood samples were collected before the first vaccination and after 2 weeks for each dose vaccination. Spike-specific binding antibodies (bAbs) in all participants and neutralizing antibodies (nAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wild-type, Delta, and Omicron variants in CPs were analyzed and presented as the geometric mean titer.
Results
Age-matched 20 HCWs and 118 CPs were included in the analysis. The bAb seroconversion rate and antibody concentrations after the first vaccination were significantly lower in CPs than in HCWs. After the third vaccination, antibody levels in CPs with a primary series of AdV were comparable to those in HCWs, but nAb titers against the Omicron variant did not quantitatively increase in CPs with AdV vaccine as the primary series. The incidence and severity of adverse reactions post-vaccination were similar between CPs and HCWs.
Conclusion
CPs displayed delayed humoral immune response after SARS-CoV-2 vaccination. The booster dose elicited comparable bAb concentrations between CPs and HCWs, regardless of the primary vaccine type. Neutralization against the Omicron variant was not robustly elicited following the booster dose in some CPs, implying the need for additional interventions to protect them from COVID-19.

Citations

Citations to this article as recorded by

Safety, immunogenicity and protective effect of sequential vaccination with inactivated and recombinant protein COVID-19 vaccine in the elderly: a prospective longitudinal study
Hong-Hong Liu, Yunbo Xie, Bao-Peng Yang, Huan-Yue Wen, Peng-Hui Yang, Jin-E Lu, Yan Liu, Xi Chen, Meng-Meng Qu, Yang Zhang, Wei-Guo Hong, Yong-Gang Li, Junliang Fu, Fu-Sheng Wang
Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
Immune response of COVID-19 vaccines in solid cancer patients: A meta-analysis
Tiantian Hua, Ru Fan, Yang Fan, Feng Chen
Human Vaccines & Immunotherapeutics.2024;[Epub] CrossRef
A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers
Urska Janzic, Urska Bidovec-Stojkovic, Peter Korosec, Katja Mohorcic, Loredana Mrak, Marina Caks, Maja Ravnik, Erik Skof, Matija Rijavec
Vaccines.2023; 11(6): 1017. CrossRef
Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients
Christopher W. Dukes, Marine Potez, Jeffrey Lancet, Barbara J. Kuter, Junmin Whiting, Qianxing Mo, Brett Leav, Haixing Wang, Julie S. Vanas, Christopher L. Cubitt, Kimberly Isaacs-Soriano, Kayoko Kennedy, Julie Rathwell, Julian Diaz Cobo, Wesley O’Nan, Br
Vaccines.2023; 12(1): 13. CrossRef

4,616 View
213 Download
4 Web of Science
4 Crossref

Urologic cancer

External Validation of the Long Short-Term Memory Artificial Neural Network-Based SCaP Survival Calculator for Prediction of Prostate Cancer Survival: Bumjin Lim, Kwang Suk Lee, Young Hwa Lee, Suah Kim, Choongki Min, Ju-Young Park, Hye Sun Lee, Jin Seon Cho, Sun Il Kim, Byung Ha Chung, Choung-Soo Kim, Kyo Chul Koo; Cancer Res Treat. 2021;53(2):558-566. Published online October 6, 2020; DOI: https://doi.org/10.4143/crt.2020.637

Abstract PDF PubReader ePub

Purpose
Decision-making for treatment of newly diagnosed prostate cancer (PCa) is complex due to the multiple initial treatment modalities available. We aimed to externally validate the SCaP (Severance Study Group of Prostate Cancer) Survival Calculator that incorporates a long short-term memory artificial neural network (ANN) model to estimate survival outcomes of PCa according to initial treatment modality. Materials and Methods The validation cohort consisted of clinicopathological data of 4,415 patients diagnosed with biopsy-proven PCa between April 2005 and November 2018 at three institutions. Area under the curves (AUCs) and time-to-event calibration plots were utilized to determine the predictive accuracies of the SCaP Survival Calculator in terms of progression to castration-resistant PCa (CRPC)–free survival, cancer-specific survival (CSS), and overall survival (OS). Results Excellent discrimination was observed for CRPC-free survival, CSS, and OS outcomes, with AUCs of 0.962, 0.944, and 0.884 for 5-year outcomes and 0.959, 0.928, and 0.854 for 10-year outcomes, respectively. The AUC values were higher for all survival endpoints compared to those of the development cohort. Calibration plots showed that predicted probabilities of 5-year survival endpoints had concordance comparable to those of the observed frequencies. However, calibration performances declined for 10-year predictions with an overall underestimation. Conclusion The SCaP Survival Calculator is a reliable and useful tool for determining the optimal initial treatment modality and for guiding survival predictions for patients with newly diagnosed PCa. Further modifications in the ANN model incorporating cases with more extended follow-up periods are warranted to improve the ANN model for long-term predictions.

Citations

Citations to this article as recorded by

Harnessing machine learning to predict prostate cancer survival: a review
Sungun Bang, Young Jin Ahn, Kyo Chul Koo
Frontiers in Oncology.2025;[Epub] CrossRef
Application of artificial intelligence in the diagnosis and treatment of urinary tumors
Mengying Zhu, Zhichao Gu, Fang Chen, Xi Chen, Yue Wang, Guohua Zhao
Frontiers in Oncology.2024;[Epub] CrossRef
Computational Intelligence in Cancer Diagnostics: A Contemporary Review of Smart Phone Apps, Current Problems, and Future Research Potentials
Somit Jain, Dharmik Naicker, Ritu Raj, Vedanshu Patel, Yuh-Chung Hu, Kathiravan Srinivasan, Chun-Ping Jen
Diagnostics.2023; 13(9): 1563. CrossRef
Development and external validation of a machine learning-based model to classify uric acid stones in patients with kidney stones of Hounsfield units < 800
Ben H. Chew, Victor K. F. Wong, Abdulghafour Halawani, Sujin Lee, Sangyeop Baek, Hoyong Kang, Kyo Chul Koo
Urolithiasis.2023;[Epub] CrossRef
Multilayer perceptron-based prediction of stroke mimics in prehospital triage
Zheyu Zhang, Dengfeng Zhou, Jungen Zhang, Yuyun Xu, Gaoping Lin, Bo Jin, Yingchuan Liang, Yu Geng, Sheng Zhang
Scientific Reports.2022;[Epub] CrossRef

6,558 View
124 Download
5 Crossref

Case Report

Oxaliplatin-Induced Immune-Mediated Thrombocytopenia: A Case Report: Hyun Sun Woo, Kyoung Hwa Lee, Phill Hoon Yoon, Su Ji Kim, Inkeun Park, Young Saing Kim, Hee Kyung Ahn, Junshik Hong, Dong Bok Shin, Sun Jin Sym; Cancer Res Treat. 2015;47(4):949-953. Published online October 28, 2014; DOI: https://doi.org/10.4143/crt.2014.052

Abstract PDF PubReader ePub

Oxaliplatin is a third-generation platinum derivative used for metastatic or advanced colorectal cancer treatment. Although myelosuppression is the most common cause of oxaliplatin-induced thrombocytopenia, rare cases of oxaliplatin-induced immunemediated thrombocytopenia are reported. We report a case of a 57-year-old woman with colon cancer who developed gum bleeding and petechiae after oxaliplatin infusion. Laboratory tests revealed grade 4 thrombocytopenia and grade 4 neutropenia. She recovered from the thrombocytopenia and accompanying neutropenia within 4 days with no recurrence following discontinuation of oxaliplatin. Physicians need to be aware of the risk of severe acute thrombocytopenia following oxaliplatin administration.

Citations

Citations to this article as recorded by

Risk Factors of Chemotherapy-Induced Thrombocytopenia After Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancies
Ju Li, Wanqing Wang, Kaipeng Jiang, Jiuwei Cui, Chang Wang, Tingting Liang, Yizhuo Wang, Shuhan Liu, Wenshuo Zhou
Journal of Gastrointestinal Cancer.2024; 55(3): 1144. CrossRef
Oxaliplatin Antibody-Related Thrombocytopenia: A Case Report
Khin Pyai, David I LeRoy, Joseph Attallah, Hosam Hakim, Zyad Kafri
Cureus.2024;[Epub] CrossRef
The Many Faces of Immune Thrombocytopenia: Mechanisms, Therapies, and Clinical Challenges in Oncological Patients
Marek Kos, Piotr Tomaka, Paulina Mertowska, Sebastian Mertowski, Julia Wojnicka, Anna Błażewicz, Ewelina Grywalska, Krzysztof Bojarski
Journal of Clinical Medicine.2024; 13(22): 6738. CrossRef
Severe ileum bleeding following adjuvant capecitabine chemotherapy for locally advanced colon cancer: a case report and review of the literature
You Zou, Shuang Liu, Jianhong Wu, Zhen Sun
World Journal of Surgical Oncology.2021;[Epub] CrossRef
A case of idiosyncratic liver injury after oxaliplatin‐induced thrombocytopenia
Shinji Honda, Masayuki Tsujimoto, Tetsuya Minegaki, Tomohiko Mori, Junji Muraoka, Kohshi Nishiguchi
Journal of Clinical Pharmacy and Therapeutics.2020; 45(2): 373. CrossRef
Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents
Benjamin K. Gersten, Tracy S. Fitzgerald, Katharine A. Fernandez, Lisa L. Cunningham
Journal of the Association for Research in Otolaryngology.2020; 21(4): 303. CrossRef
Oxaliplatin-Induced Thrombocytopenia: A Case Report and Review of Pathophysiology of Various Speculative Mechanisms
Haider Ghazanfar, Iqra Nawaz, Nisha Ali
Cureus.2020;[Epub] CrossRef
Oxaliplatin Treatment Alters Systemic Immune Responses
Vanesa Stojanovska, Monica Prakash, Rachel McQuade, Sarah Fraser, Vasso Apostolopoulos, Samy Sakkal, Kulmira Nurgali
BioMed Research International.2019; 2019: 1. CrossRef
Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study
Katia Bencardino, Gianluca Mauri, Alessio Amatu, Federica Tosi, Erica Bonazzina, Laura Palmeri, Marialuisa Querques, Federica Ravera, Alberto Menegotto, Elisa Boiani, Andrea Sartore-Bianchi, Salvatore Siena
Clinical Colorectal Cancer.2016; 15(3): 213. CrossRef

12,696 View
116 Download
10 Web of Science
9 Crossref

Original Article

Cost-Effectiveness of Liver Cancer Screening in Adults at High Risk for Liver Cancer in the Republic of Korea: Young Hwa Lee, Kui Son Choi, Jae Kwan Jun, Mina Suh, Hoo-Yeon Lee, Youn Nam Kim, Chung Mo Nam, Eun-Cheol Park, Woo-Hyun Cho; Cancer Res Treat. 2014;46(3):223-233. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.223

Abstract PDF PubReader ePub

Purpose
This study was conducted in order to determine the most cost-effective strategy, in terms of interval and age range, forliver cancer screening in the high-risk population of Korea. Materials and Methods A stochastic modelwas used to simulate the cost-effectiveness ofliver cancer screening by combined ultrasonography and alpha-fetoprotein testing when varying both screening intervals and age ranges. The effectiveness of these screening strategies in the high-risk population was defined as the probability of detecting preclinical liver cancer, and costwas based on the direct cost ofthe screening and confirmative tests. Optimal cost-effectiveness was determined using the incremental cost-effectiveness ratio. Results Among the 36 alternative strategies, one-year or two-year interval screening for men aged between 50 and 80 years, six-month or one-year interval screening for men aged between 40 and 80 years, and six-month interval screening for men aged between 30 and 80 years were identified as non-dominated strategies. For women, identified non-dominated strategies were: one-year interval screening between age 50 and 65 years, one-year or six-month interval screening between age 50 and 80 years, six-month interval screening between age 40 and 80 years, and six-month interval screening between age 30 and 80 years. Conclusion In Korea, a one-year screening interval for men aged 50 to 80 years would be marginally cost-effective. Further studies should be conducted in order to evaluate effectiveness of liver cancer screening, and compare the cost effectiveness of different liver cancer screening programs with a final outcome indicator such as qualityadjusted life-years or disability-adjusted life-years.

Citations

Citations to this article as recorded by

Alcoholic liver disease in relation to cancer incidence and mortality: Findings from a large, matched cohort study in South Korea
Thi Phuong Thao Tran, Minji Han, Ngoc Minh Luu, Jin‐Kyoung Oh
Cancer Medicine.2023; 12(7): 8754. CrossRef
A Systematic Review and Narrative Synthesis of Health Economic Evaluations of Hepatocellular Carcinoma Screening Strategies
Anh Le Tuan Nguyen, Hoa Thi Thu Nguyen, Kwang Chien Yee, Andrew J. Palmer, Christopher Leigh Blizzard, Barbara de Graaff
Value in Health.2021; 24(5): 733. CrossRef
Disparities in Liver Cancer Surveillance Among People With Disabilities
Jae Youn Seo, Dong Wook Shin, Su Jong Yu, Jin Hyung Jung, Kyungdo Han, In Young Cho, So Young Kim, Kui Son Choi, Jong Heon Park, Jong Hyock Park, Ichiro Kawachi
Journal of Clinical Gastroenterology.2021; 55(5): 439. CrossRef
The Impact of National Surveillance for Liver Cancer: Results from Real-World Setting in Korea
Jin Won Kwon, Ha Jin Tchoe, Jayoun Lee, Jae Kyung Suh, Jeong-Hoon Lee, Sangjin Shin
Gut and Liver.2020; 14(1): 108. CrossRef

12,224 View
105 Download
5 Web of Science
4 Crossref

First
Prev
Page of 1
Next
Last

Search